Da-Yong Lu*, Ting-Ren Lu, Jian Ding, Bin Xu, Jin-Yu Che and Hong-Ying Wu Pages 44 - 55 ( 12 )
Background: Clinical cancer treatment and therapy have been gradually improved by experimental and clinical advancements worldwide, especially after the advent of different types of individualized cancer therapy (ICT).
Objective: Despite the longest history of anticancer drug sensitivity testing (DST) among ICT, its therapeutic applications for clinical cancer trials need to be updated.
Methods: DST techniques are widely diversified and improved a great deal, but they have not been matured to cure all cancer patients in clinics.
Results: The retrospection and panorama of historic and evolutionary developments of DST including clinical relevance, advantageous, technical cautions, limitations of varied models and methodologies at present stage are addressed.
Conclusion: Future directions and novel ideas must be established.
Anticancer drugs, cancer stem cell, clinical cancer therapy, drug combinations, drug sensitivity test, individualized cancer therapy, neoplasm metastasis.
School of Life Sciences, Shanghai University, Shanghai 200444, P.R. China.